AbilityPharma, the biopharmaceutical company and CataloniaBio & HealthTech member, has been granted with €2 million of non-dilutive funding to speed up the regulatory path for its anticancer autophagy inducer ABTL0812.

DeepUll, CataloniaBio & HealthTech member, has raised €13 million in a Series B financing round. The medical diagnostics company is developing culture-free, affordable diagnostic solutions for the early identification of sepsis and other acute infections.

ZeClinics has recently been awarded an EIC-Pathfinder Challenge by the European Innovation Council (EIC). Pathfinder are grants targeting specific strategic priorities with early-stage development of radically new technology and high-risk/high-gain breakthrough research. EdiGenT is one of the 8 selected projects over 132 eligible proposals in the strategic area of “Emerging technologies in cell and gene therapy”.

The Parc Taulí has obtained the license to manufacture customized health products in its facilities by the Generalitat de Catalunya. This license will allow the 3D Laboratory to manufacture in its facilities and supply to other hospital centers.  

A symposium, held in the framework of the PER-IADR in Marseille, has made a retrospective of the measures recommended in dentistry to protect against SARS-CoV-2 coronavirus infections, after more than two years of pandemic. Dentaid Research Center, members of CataloniaBio & HealthTech, stress the importance of establishing a protection protocol prior to the dental procedure, which includes mouth strips with highly effective antiseptics to control bacterial and viral infection during dental procedures.

Devicare, one of the leading biotechnology companies in urology in Spain, presents Canoxidin® to the market; a first-in-class oral treatment that will allow all Spanish urologists to reduce the risk of calcification of urological devices (bladder catheters, ureteral catheters or nephrostomy tubes) by up to 8 times according to the results of Torrecilla et al, 2020 published in BMC Urology.

Abzu, a CataloniaBio & HealthTech member, is one of 75 of Europe’s high-potential startups selected in the extremely competitive June cutoff of the 2022 European Innovation Council (EIC) Accelerator program.

Dr Marc Güell received the Ángela Ruiz Robles 2022 National Research Award for Young People, in the field of technology transfer, awarded by the Ministry of Science and Innovation of Spain.

These are data from the study "Strategic value chains in Catalan industry: analysis of dependencies and technological specialisation", by the Director of Economic Analysis of the Barcelona Chamber of Commerce, Carme Poveda. It is the 20th in the Papers collection of the Observatori de l'Indústria del Departament d'Empresa i Treball de la Generalitat.

A total of six Catalan companies are among the beneficiaries of PERTE in the section for cutting-edge health. The Ministry of Industry, Commerce and Tourism has published the provisional resolution of the PERTE with a total of 17 companies included in the list, of which six in Catalonia and three members of CataloniaBio & HealthTech: Biorem, Medichem and Vecmedical.

The venture capital, Invivo Capital, a member of CataloniaBio & HealthTech, has completed the sale of Versantis, the Swiss biotechnology company. In an agreement valued at 140 million euros, it is the second transaction in the HealthEquity portfolio, the firm's first vehicle. Last year they closed the transfer of Sanifit for 205 million to Vifor Pharma, which was the largest operation in the biotechnology sector in Spain.

Affirma Biotech, CataloniaBio & HealthTech member, announced today the closing of its seed capital round with a total of 600,000 euros that the company will invest in the optimization of its preclinical candidates. During the past year a total amount of 960.000 euros in funding has been raised by the company from several business angels with extensive experience in the biotech industry. The lead investors of this round are Alfons Hidalgo (founder of Infinitec), Luis Ruiz Avila and Reig Jofre Investments, among others. Affirma Biotech also has Start-up Capital aid, granted by Acció. 

Tailor Surgery is the new spin-off of the Parc Taulí Research and Innovation Institute (I3PT), a CataloniaBio & HealthTech member, which is formed with the aim of globally marketing the line of customized instruments and customized implants in traumatology of the 3D Laboratory of the Institute.

La gestora de capital risc Asabys ha anunciat el llançament d’un nou fons, Sabadell Asabys Health Innovation Investments II (SAHII 2), per continuar invertint en innovació tecnològica en salut i consolidar la seva posició com a firma de capital privat líder en aquest àmbit al sud d’Europa.

Minoryx Therapeutics, membre de CataloniaBio & HealthTech, ha presentat la sol·licitud d'autorització de comercialització (MAA) del seu fàrmac leriglitazona a l'Agència Europea de Medicaments (EMA) per al tractament d’homes adults amb adrenoleucodistròfia lligada al cromosoma X (X-ALD). L'EMA ja ha validat el dossier de la sol·licitud i ara es troba en procés de revisió del Comitè de Medicaments d'Ús Humà (CHMP).

Specipig, member of CataloniaBio &HealthTech, has opened a neonatal intensive care unit (NICU) at its research facilities in the Barcelona area to continue responding to the global demand for preclinical Contract Research Organization (CRO) services.

Vall d’Hebron Research Institute (VHIR) and Oncoheroes Biosciences, a biotechcompany exclusively focused on advancing new therapies for children withcancer, announced they have entered a partnership to collaborate in thediscovery and development of innovative therapies for pediatric sarcomas.

Aniling, a biotech company that develops solutions based on next-generation genomic and epigenomic sequencing (NGS) methods for precision oncology, has obtained CE certification for its first in vitro diagnostic (IVD) tests for chronic lymphocytic leukaemia, colorectal cancer and liquid. The biotech is a  CataloniaBio & HealthTech member and one of the finishers of the IVD Accelerator  Programme, promoted by the association to help accelerate start-ups and companies in the field of in vitro diagnostics. The CE mark authorises the company to market the tests throughout Europe.

Inbiomotion SL, a company developing a unique single-gene-based biomarker for the personalized adjuvant treatment of early-stage (stage I-III) breast cancer patients, announces the results of comparing the clinical efficacy of implementing the proprietary MAFTEST® for selection of patients for adjuvant bisphosphonates therapy with current clinical guidance. Inbiomotion is participated by Ysios Capital, both CataloniaBio & HealthTech members.

CataloniaBio & HealthTech brought together nearly 400 executives, entrepreneurs, investors  and stakeholders in the biomedical and health sector in Catalonia at a new  edition of the summer barbecue on 14 July at the Specipig facilities. The association and the sector are growing, and the attendance figures reflect this. This year the BBQ has had the support as silver sponsors of Asabys, Caixa Capital Risc, Capital Cell, GENESIS Biomed, Inveready, Invivo  Ventures and Ysios Capital.